Download presentation
Presentation is loading. Please wait.
Published byΘάλεια Αγγελοπούλου Modified over 5 years ago
1
Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx H. Hauswald, A.D. Jensen, J. Krauss, R. Haselmann, K. Lossner, S. Hartmann, C. Windemuth-Kieselbach, M.W. Münter, J. Debus Clinical and Translational Radiation Oncology Volume 13, Pages (November 2018) DOI: /j.ctro Copyright © 2018 The Authors Terms and Conditions
2
Fig. 1 Flow-chart of the TPF-C-HIT trial.
Clinical and Translational Radiation Oncology , 64-73DOI: ( /j.ctro ) Copyright © 2018 The Authors Terms and Conditions
3
Fig. 2 EORTC-QLQ-C30 Questionnaire functional results (mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months). Clinical and Translational Radiation Oncology , 64-73DOI: ( /j.ctro ) Copyright © 2018 The Authors Terms and Conditions
4
Fig. 3a EORTC-QLQ-C30 Questionnaire gastrointestinal symptom scales (mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months). Clinical and Translational Radiation Oncology , 64-73DOI: ( /j.ctro ) Copyright © 2018 The Authors Terms and Conditions
5
Fig. 3b EORTC-QLQ-C30 Questionnaire non-gastrointestinal symptom scales (mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months). Clinical and Translational Radiation Oncology , 64-73DOI: ( /j.ctro ) Copyright © 2018 The Authors Terms and Conditions
6
Fig. 4a EORTC QLQ H&N 35 single item scale scores (oral part, mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months). Clinical and Translational Radiation Oncology , 64-73DOI: ( /j.ctro ) Copyright © 2018 The Authors Terms and Conditions
7
Fig. 4b EORTC QLQ H&N 35 single item scale scores (gastrointestinal, mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months). Clinical and Translational Radiation Oncology , 64-73DOI: ( /j.ctro ) Copyright © 2018 The Authors Terms and Conditions
8
Fig. 4c EORTC QLQ H&N 35 single item scale scores (other symptoms, mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months). Clinical and Translational Radiation Oncology , 64-73DOI: ( /j.ctro ) Copyright © 2018 The Authors Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.